BNT162b2 vaccine-induced humoral and cellular responses against SARS-CoV-2 variants in Systemic Lupus Erythematosus
Preprint
- 8 July 2021
- preprint
- research article
- Published by Cold Spring Harbor Laboratory
Abstract
Objectives Our aims were to evaluate Systemic Lupus Erythematosus (SLE) disease activity and SARS-CoV-2 specific immune responses after BNT162b2 vaccination. Methods In this prospective study, disease activity and clinical assessments were recorded from the first dose of vaccine, until day 15 after the second dose in 126 SLE patients. SARS-CoV-2 antibody responses were measured against wild-type spike antigen while serum-neutralizing activity was assessed against the SARS-CoV-2 historical strain and variants of concerns (VOCs). Vaccine-specific T-cell responses were quantified by Interferon (IFN)-γ release assay after the second dose. Results BNT162b2 was well tolerated and no statistically significant variations of BILAG and SLEDAI scores were observed throughout the study in SLE patients with active and inactive disease at baseline. Mycophenolate Mofetil (MMF) and Methotrexate (MTX) treatments were associated with drastically reduced BNT162b2 antibody-response (β=-78; p=0.007, β=-122; pConclusion MMF, MTX and poor baseline humoral immune status, particularly: low naïve B cell frequencies, are independently associated with impaired BNT162b2 mRNA antibody response, delineating SLE patients who might need adapted vaccine regimens and follow-up. What is already known about this subject? BNT162b2 efficacy and safety has been described in studies mixing different RMDs What does this study add? No serious adverse effects, nor SLE flares have been documented after BNT162b2 in SLE patients. Not only MMF and MTX, but also a poor humoral immune status at baseline impair vaccine antibody response Albeit decreased, serum neutralizing activity against VOCs is conferred to vaccine-responders. How might this impact on clinical practice or future developments? These parameters could be helpful for physicians to delineate which patients should have antibody measurement after full BNT162b2 vaccination and should be proposed a third injection of BNT162b2 vaccine.Keywords
Other Versions
- Published version: Version Annals Of The Rheumatic Diseases, 81, preprints
This publication has 53 references indexed in Scilit:
- Antibody response is reduced following vaccination with 7-valent conjugate pneumococcal vaccine in adult methotrexate-treated patients with established arthritis, but not those treated with tumor necrosis factor inhibitorsArthritis & Rheumatism, 2011
- Factors influencing the efficacy of two injections of a pandemic 2009 influenza A (H1N1) nonadjuvanted vaccine in systemic lupus erythematosusArthritis & Rheumatism, 2011
- Abnormalities of B cell subsets in patients with systemic lupus erythematosusJournal of Immunological Methods, 2011
- An assessment of disease flare in patients with systemic lupus erythematosus: a comparison of BILAG 2004 and the flare version of SELENAAnnals Of The Rheumatic Diseases, 2010
- Combined Oral Contraceptives in Women with Systemic Lupus ErythematosusThe New England Journal of Medicine, 2005
- The Effect of Combined Estrogen and Progesterone Hormone Replacement Therapy on Disease Activity in Systemic Lupus Erythematosus: A Randomized TrialAnnals of Internal Medicine, 2005
- BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group's disease activity index for patients with systemic lupus erythematosusRheumatology, 2005
- Definition and treatment of lupus flares measured by the BILAG indexRheumatology, 2003
- Disturbed Peripheral B Lymphocyte Homeostasis in Systemic Lupus ErythematosusThe Journal of Immunology, 2000
- Updating the American college of rheumatology revised criteria for the classification of systemic lupus erythematosusArthritis & Rheumatism, 1997